Difference between revisions of "Gastric cancer - historical"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...")
 
Line 125: Line 125:
 
|[[Gastric_cancer#ECF_3|ECF]]
 
|[[Gastric_cancer#ECF_3|ECF]]
 
| style="background-color:#d73027" |Inferior OS
 
| style="background-color:#d73027" |Inferior OS
 +
|-
 +
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2648 Vanhoefer et al. 2000 (EORTC 40902)]
 +
| style="background-color:#1a9851" |Phase III (C)
 +
|1. ELF<br> 2. FUP
 +
| style="background-color:#ffffbf" |Seems not superior
 
|-
 
|-
 
|}
 
|}
Line 137: Line 142:
 
# Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [http://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8996151 PubMed]
 
# Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [http://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8996151 PubMed]
 
## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://www.nature.com/articles/6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10390007 PubMed]
 
## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://www.nature.com/articles/6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10390007 PubMed]
 +
# '''EORTC 40902:''' Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000 Jul;18(14):2648-57. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.14.2648 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10894863 PubMed]
  
 
==FEMTX {{#subobject:412e7b|Regimen=1}}==
 
==FEMTX {{#subobject:412e7b|Regimen=1}}==

Revision as of 04:08, 13 November 2018

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main gastric cancer page for current regimens.

8 regimens on this page
9 variants on this page


Adjuvant therapy

Fluorouracil & Mitomycin

back to top

Regimen

Study Evidence Comparator Efficacy
Allum et al. 1989 Phase III (E) Observation Seems not superior
Nakazato et al. 1994 Phase III (C) 5-FU, Mitomycin, PSK Seems to have inferior OS

Preceding treatment

  • Surgery

Chemotherapy

References

  1. Allum WH, Hallissey MT, Kelly KA; British Stomach Cancer Group. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989 Mar 18;1(8638):571-4. link to original article PubMed
  2. Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J; Study Group of Immunochemotherapy with PSK for Gastric Cancer. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994 May 7;343(8906):1122-6. link to original article PubMed

Metastatic or locally advanced disease, first-line

Best supportive care

back to top

Regimen

Study Evidence Comparator Efficacy
Pyrhönen et al. 1995 Phase III (C) FEMTX Inferior OS

No antineoplastic treatment.

References

  1. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. link to original article link to PMC article PubMed

FAM

back to top

FAM: Fluorouracil, Adriamycin (Doxorubicin), Mitomycin

Regimen

Study Evidence Comparator Efficacy
Cullinan et al. 1985 Phase III (E) 1. 5-FU
2. FA 		Seems not superior
Wils et al. 1991 Phase III (C) FAMTX Inferior OS

Chemotherapy

References

  1. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. link to original article PubMed
  2. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. link to original article PubMed

FAMTX

back to top

FAMTX: Fluorouracil, Adriamycin (Doxorubicin), MTX (Methotrexate)

Regimen

Study Evidence Comparator Efficacy
Wils et al. 1991 Phase III (E) FAM Superior OS
Kelsen et al. 1992 Phase III (E) EAP Seems not superior
Webb et al. 1997 Phase III (C) ECF Inferior OS
Vanhoefer et al. 2000 (EORTC 40902) Phase III (C) 1. ELF
2. FUP 		Seems not superior

Chemotherapy

References

  1. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, Duez N. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827-31. link to original article PubMed
  2. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541-8. link to original article PubMed
  3. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. link to original article PubMed
    1. Update: Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. link to original article link to PMC article PubMed
  4. EORTC 40902: Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol. 2000 Jul;18(14):2648-57. link to original article PubMed

FEMTX

back to top

FEMTX: Fluorouracil, Epirubicin, MTX (Methotrexate)

Regimen

Study Evidence Comparator Efficacy
Pyrhönen et al. 1995 Phase III (E) Best supportive care Superior OS

Chemotherapy

References

  1. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995 Mar;71(3):587-91. link to original article link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Gastric_cancer_-_historical&oldid=32427"